CeQur buys assets from J&J’s diabetes care company Calibra Medical

18 July 2018 (Last Updated November 22nd, 2018 11:24)

Swiss insulin devices provider CeQur has purchased certain assets from Johnson & Johnson Diabetes Care Companies subsidiary Calibra Medical for an undisclosed amount.

CeQur buys assets from J&J’s diabetes care company Calibra Medical
CeQur has acquired a three-day, wearable, on-demand bolus insulin-delivery device from Calibra Medical. Credit: PRNewsfoto/CeQur.

Swiss insulin devices provider CeQur has purchased certain assets from Johnson & Johnson Diabetes Care Companies subsidiary Calibra Medical for an undisclosed amount.

As part of the acquisition, CeQur gains exclusive worldwide licence to Calibra’s wearable, on-demand insulin delivery system that was formerly called OneTouch Via.

The system has been designed for the simple and convenient delivery of rapid-acting insulin at mealtime.

“As part of the acquisition, CeQur gains exclusive worldwide licence to Calibra’s wearable, on-demand insulin delivery system that was formerly called OneTouch Via.”

After the transfer of the associated manufacturing equipment, CeQur is planning to relaunch the Calibra system in mid next year under a new name.

The system is expected to complement CeQur’s basal and bolus insulin-infusion device, PAQ, which is also a wearable product developed to allow simple, discreet insulin delivery.

CeQur believes that the wearable devices will eliminate the need for multiple injections each day.

CeQur CEO Robert Farra said: “Clinical studies and real-world experience have shown that wearable, on-demand insulin delivery provides an ideal solution to the pervasive challenge of mealtime insulin delivery.

“The Calibra device is a perfect complement to PAQ, our basal and bolus insulin-infusion device. Both wearable devices provide simple, discreet, three-day insulin delivery without the barriers and discomfort created by injections.”

A recent clinical study reported to have demonstrated favourable clinical outcomes when the Calibra device’s capability to initiate and maintain bolus insulin dosing was compared to that of insulin pens.

Conducted in 278 type 2 diabetes patients at 62 sites, the trial showed that the Calibra system delivered positive clinical benefits, comparatively less glycaemic variability, significantly improved ease-of-use and patient satisfaction scores.

The safety profile of the device was found to be similar to the insulin pens.